Evaluation of primary aldosteronism testing in hypertensive patients with SLE in a tertiary hospital
S L E is a chronic multisystem autoimmune disease in which cardiovascular disease is a leading cause of mortality, with a ...
Obinutuzumab B-cell depleting therapy is more effective than standard care in treating patients with active proliferative lupus nephritis.
The FDA has accepted an investigational new drug application for ALLO-329, an allogeneic chimeric antigen receptor T-cell ...
Adicet Bio, Inc. (NASDAQ:ACET), currently trading at $0.99 with a market capitalization of $81.7 million, is a clinical-stage biopharmaceutical company focused on developing novel cell therapies based ...
Adding the anti-CD20 monoclonal antibody obinutuzumab (Gazyva) to standard therapy for lupus nephritis is more efficacious ...
More than 50% of patients with systemic lupus erythematosus (SLE) develop lupus nephritis (LN) during the disease, which may ...
Conduit Pharmaceuticals partners with Charles River to evaluate the efficacy of its lead programme in a pre-clinical lupus model, utilizing ...
Objective Combination therapy with rituximab and belimumab is a novel treatment strategy for severe SLE and lupus nephritis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback